REFERENCES
- Sulkowski M, Thomas D, Chaisson R, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
- Brinker M, Wit F, Wertheim-van Killen P, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895–2902.
- Saves M, Vandentorren S, Daucourt V, et al. Severe he-patic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998. AIDS. 1999;13:F115–F121.
- D'Arminio A, Bugarini R, Pezzotti P, et al. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J AIDS. 2001;28:114–123.
- Gisolf E, Dreezen C, Danner S, et al. Risk factors for hepatotoxicity in HIV-1 infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 2000;31:1234–1239.
- Reisler R, Liou S, Servoss J, et al. Incidence of hepatotox-icity and mortality in 21 adult antiretroviral treatment trials. In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires. Abstract 43.
- Sanne I. Severe liver toxicity in patients receiving two nucleoside analogues and a non-nucleoside reverse tran-scriptase inhibitor. AIDS. 2000;14\(suppl 4):S12.
- Centers for Disease Control and Prevention. Serious ad-verse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures-worldwide, 1997–2000. JAMA. 2001285: 402–403.
- Martinez E, Blanco J, Arnaiz A, et al. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 2001;15:1261–1268.
- Nuriez M, Lana R, Mendoza J, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J AIDS. 2001;27:426–431.
- Piroth L, Grappin M, Segro C, et al. Recurrent NNRTI-induced hepatotoxicity in an HIV-HCV coinfected patients. Ann Pharmacother. 2000;34:534–535.
- AIDS Clinical Trials Group. Table of Grading Severity of Adult Adverse Experiences. Rockville, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases; 1996.
- Puoti M, Patroni A, Pan L, et al. Hepatotoxicity associated with non-nucleoside reverse transcriptase inhibitors in 427 adults infected with HIV. In: Program and abstracts of the Eighth European Conference on Clinical Aspects and Treatment of HIV Infection; October 2001; Athens. Abstract 129.
- Sulkowski M, Mehta S, Thomas D, et al. Hepatotoxicity associated with NNRTI use: role of drugs and chronic viral hepatitis. In: Program and abstracts of the Eighth Confer-ence of Retroviruses and Opportunistic Infections; Febru-ary 2001; Chicago, Illinois. Abstract 618.
- Arnaiz J, Martinez E, Cruceta A, et al. Efavirenz-associated liver toxicity: a prospective cohort study. In: Program and abstracts of the Eighth Conference of Retroviruses and Opportunistic Infections; October 2001; Athens. Abstract 130.
- Dieterich D, Stern J, Robinson P, et al. Analyses of four key clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B & C seropositivity, and baseline liver function tests. In: Program and abstracts of the First IAS Conference on HIV Pathogen-esis and Treatment; July 2001; Buenos Aires. Abstract 44.
- Bennet C, Johnson S, Lynch P, et al. Hepatic and cutane-ous toxicity attributed to nevirapine (NVP). In: Program and abstracts of the First IAS Conference on HIV Pathogenesis and Treatment; July 2001; Buenos Aires. Abstract 45.
- Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapine-associated exhantema using slow dose scalation and/or corticosteroids. AIDS. 2000;14:2153–2157.
- Torriani F, Soriano V. Chronic hepatitis C in HIV-infected individuals. AIDS Rev. 2000;2:168–177.
- Pérez-Olmeda M, Nunez M, Romero M, et al. Pegylated interferon alpha-2b plus ribavirin as therapy for HIV-in-fected patients with chronic hepatitis C. AIDS. In press.
- Gonzalez de Requena D, Nunez M, Jiménez-Nacher I, Soriano V. Liver toxicity due to nevirapine. AIDS. 2002;16:290-291.